Abstract:BACKGROUND:An intimidating challenge to transporting drugs into the brain parenchyma is the presence of the blood-brain barrier (BBB). Glucose is an essential nutritional substance for brain function sustenance, which cannot be synthesized by the brain. Its transport primarily depends on the glucose transporters on the brain capillary endothelial cells. In this paper, the brain-targeted properties of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers were compared and evaluated to establish an optimized drug-delivery system. METHODS:Coumarin 6-loaded liposomes (GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-LIP) composed of phospholipids and glucose-derived cholesterols were prepared by thin-film dispersion-ultrasound method. The BBB model in vitro was developed to evaluate the transendothelial ability of the different liposomes crossing the BBB. The biodistribution of liposomes in the mice brains was identified by in vivo and ex vivo nearinfrared fluorescence imaging and confocal laser scanning microscopy and further analyzed quantitatively by high-performance liquid chromatography. RESULTS:Glucose-derived cholesterols were synthesized and identified, and coumarin 6-loaded liposomes were prepared successfully. The particle sizes of the four types of glucose-modified liposomes were around or smaller than 100 nm with a polydispersity index less than 0.300. GLU400-LIP, GLU1000-LIP, and GLU2000-LIP achieved higher cumulative cleared volumes on BBB model in vitro after 6 hours compared with GLU200-LIP (P < 0.05) and were significantly higher than that of the conventional liposome (P < 0.001). The qualitative and quantitative biodistribution results in the mice showed that the accumulation of GLU1000-LIP in the brain was the highest among all the groups (P < 0.01 versus LIP). CONCLUSION:The data indicated that GLU400-LIP, GLU1000-LIP, and GLU2000-LIP all possess the potential of brain targeting, among which GLU1000-LIP, as a promising drug-delivery system, exhibited the strongest brain delivery capacity.

Synthesis of Multivalent Glucosides with High Affinity for GLUT1 Transporter

Design, Synthesis and Biological Evaluation of Multivalent Glucosides with High Affinity As Ligands for Brain Targeting Liposomes.

Design and Synthesis of Glucose-Cholesterol As Ligand for Brain Targeting Liposomes

Synthesis of Multivalent Galactosides with High Affinity for the Hepatic Asialoglycoprotein Receptor

Design, Synthesis And In Vivo Evaluation Of Sulfhydryl Beta-D-Glucose Cholesterols As Ligands For Brain Targeting Liposomes

In Vitro and in Vivo Investigation of Glucose-Mediated Brain-Targeting Liposomes.

Investigation of glucose-modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting.

Design and synthesis of Ibuprofen prodrugs for brain target delivery using D-glucose as a vector

Design, Synthesis and Biological Evaluation for Docetaxel- Loaded Brain Targeting Liposome with "Lock-In'' Function

Synthesis of Multivalent Galactosides as Targeting Ligand for Gene Delivery

Synthesis of a Novel Tri-Antennary Galactoside with High Hepatocyte Targeting

Synthesis of Glutamic Acid-based Cluster Galactosides and Their Binding Affinities with Liver Cells

Design and Synthesis of GLUT1 Mediated Brain Targeting Prodrug of Desvenlafaxine

Enhanced Brain Targeting of Tegafur Using Novel Lactyl Cholesterol Liposome As a Carrier

Dual-targeting for Brain-Specific Liposomes Drug Delivery System: Synthesis and Preliminary Evaluation

Synthesis of a Novel Multivalent Galactoside with High Hepatocyte Targeting for Gene Delivery

Design, Synthesis and Biological Evaluation of Brain Targeting L-Ascorbic Acid Prodrugs of Ibuprofen with "Lock-In" Function

Synthesis of a Series of Multivalent Homo-, and Heteroglycosides and Their Anti-Adhesion Activities

Liposomes Actively Recognizing the Glucose Transporter GLUT(1) and Integrin Alpha(v)beta(3) for Dual-Targeting of Glioma

Biotin and Glucose Co-Modified Multi-Targeting Liposomes for Efficient Delivery of Chemotherapeutics for the Treatment of Glioma